The nine price cervical cancer vaccine is available in China for 16 to 26 year old women.
http://news.jnnc.com//jinan/2018/0430/674438.shtml
Xinhua
reporter from the State Administration of Drug Administration (State Drug Administration) on 29 days, the nine price HPV vaccine used to prevent cervical cancer was approved in our country. The vaccine is the first vaccine to prevent cancer in the world. It is also the first attempt by humans to eradicated a cancer through vaccines.
at present, the global HPV vaccine has three kinds, including two valence, four valence and nine valence. The price represents the vaccine preventable virus species. The two price applies to women aged 9 to 25. The four price applies to women aged 20 to 45. The nine valent HPV vaccine approved in China is suitable for women aged 16 to 26 years to prevent precancerous or atypical lesions such as cervical cancer caused by HPV.
the two and quadruvalent vaccines currently available in China can prevent and control the risk of 84.5% cervical cancer, while nine valent vaccines can prevent 92.1% of cervical cancer. Vaccines are usually administered in 3 doses for 6 months before they are effective. The public can choose different types of HPV vaccine according to their age and economic status. At this point, all the HPV vaccine varieties used in the world are available in China, which can better meet the public's different needs for vaccination and provide new effective means for the prevention of cervical cancer.
according to the person in charge of the State Administration of drug administration, the HPV vaccine is a special protein shell on the virus to cause the immunity of the human body. The vaccine itself is not a virus, it is a protein without the function of the virus and does not cause the virus infection. The State Drug Administration requires enterprises to develop risk management and control plans and carry out post marketing research as required.